Európska únia - estónčina - EMA (European Medicines Agency)

alexion europe sas - sebelipase alfa - lipiidide ainevahetus, kaasasündinud vead - muud alimentary seedetrakti ja ainevahetust tooted, - kanuma on näidustatud pikaajalise ensüümi asendusravi (ert) kasutamisel kõikide lüsosomaalse happe lipaasi (lal) puudulikkusega patsientidel.

Európska únia - estónčina - EMA (European Medicines Agency)

alexion europe sas - eculizumab - hemoglobinuuria, paroksüsmaalne - immunosupressandid - soliris on näidatud täiskasvanute ja laste raviks:paroxysmal öise haemoglobinuria (pnh). tõendeid kliinilise kasu on näidanud patsientidel haemolysis kliiniliste sümptomite(s) soovituslik kõrge haiguse aktiivsusega, sõltumata sellest, vereülekande ajalugu (vt lõik 5. ebatüüpiline hemolüütilis-ureemilise sündroomi (ahus). soliris on näidustatud täiskasvanute raviks:tulekindlad generaliseerunud myasthenia gravis (gmg) patsientidel, kes on anti-atsetüülkoliin retseptori (achr) antikeha-positiivsete (vt lõik 5. neuromyelitis optica spectrum disorder (nmosd) patsientidel, kes on anti-aquaporin-4 (aqp4) antikeha-positiivsete koos relapsing haiguse kulg.

Európska únia - estónčina - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuuria, paroksüsmaalne - selektiivsed immunosupressandid - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Estónsko - estónčina - Ravimiamet

cheplapharm arzneimittel gmbh - kandesartaan - tablett - 16mg 100tk; 16mg 15tk; 16mg 90tk; 16mg 14tk; 16mg 300tk; 16mg 30tk; 16mg 28tk; 16mg 56tk; 16mg 250tk

Estónsko - estónčina - Ravimiamet

gruenenthal gmbh - rosuvastatiin - õhukese polümeerikattega tablett - 5mg 7tk; 5mg 30tk; 5mg 90tk; 5mg 14tk; 5mg 15tk; 5mg 98tk; 5mg 28tk; 5mg 100tk; 5mg 42tk

Estónsko - estónčina - Ravimiamet

cheplapharm arzneimittel gmbh - kandesartaan+hüdroklorotiasiid - tablett - 32mg+12,5mg 300tk; 32mg+12,5mg 7tk

Estónsko - estónčina - Ravimiamet

cheplapharm arzneimittel gmbh - kandesartaan - tablett - 32mg 250tk; 32mg 7tk; 32mg 28tk; 32mg 98tk; 32mg 30tk; 32mg 100tk

Estónsko - estónčina - Ravimiamet

cheplapharm arzneimittel gmbh - kandesartaan+hüdroklorotiasiid - tablett - 16mg+12,5mg 30tk; 16mg+12,5mg 90tk; 16mg+12,5mg 300tk; 16mg+12,5mg 14tk; 16mg+12,5mg 98tk

Estónsko - estónčina - Ravimiamet

laboratoires juvise pharmaceuticals - anastrosool - õhukese polümeerikattega tablett - 1mg 84tk; 1mg 28tk; 1mg 98tk; 1mg 300tk; 1mg 20tk; 1mg 30tk; 1mg 100tk

Estónsko - estónčina - Ravimiamet

gruenenthal gmbh - rosuvastatiin - õhukese polümeerikattega tablett - 10mg 90tk; 10mg 42tk; 10mg 7tk; 10mg 28tk; 10mg 14tk; 10mg 100tk; 10mg 15tk; 10mg 30tk